Real-life experience with the specific reversal agent idarucizumab for the management of emergency situations in dabigatrantreated patients: a series of 11 cases
The result's identifiers
Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216208%3A11150%2F17%3A10365940" target="_blank" >RIV/00216208:11150/17:10365940 - isvavai.cz</a>
Alternative codes found
RIV/00179906:_____/17:10365940
Result on the web
<a href="http://dx.doi.org/10.1007/s11239-017-1476-2" target="_blank" >http://dx.doi.org/10.1007/s11239-017-1476-2</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.1007/s11239-017-1476-2" target="_blank" >10.1007/s11239-017-1476-2</a>
Alternative languages
Result language
angličtina
Original language name
Real-life experience with the specific reversal agent idarucizumab for the management of emergency situations in dabigatrantreated patients: a series of 11 cases
Original language description
Non-vitamin K antagonist oral anticoagulants (NOACs) have a favorable benefit-risk profile compared with vitamin K antagonists. However, the lack of specific reversal agents has made the management of some patients receiving long-term treatment with NOACs problematic in emergency situations such as major bleeding events or urgent procedures. Idarucizumab, a fully humanized Fab antibody fragment that binds specifically and with high affinity to dabigatran, was recently approved for use in adult patients treated with dabigatran when rapid reversal of its anticoagulant effect is required. Clinical experience with idarucizumab is currently limited. We report 11 real-life clinical cases in which idarucizumab was used after multidisciplinary consultation in a variety of emergency situations including severe postoperative bleeding, emergency high-bleeding-risk surgery (hip/spine surgery and neurosurgery), invasive diagnostic testing (lumbar puncture), intracranial bleeding (pre-pontine subarachnoid hemorrhage and lobar intracerebral hemorrhage) and thrombolysis with recombinant tissue plasminogen activator for acute ischemic stroke. This case series illustrates the role of idarucizumab in improving patient safety in rare emergency situations requiring rapid reversal of the anticoagulant effect of dabigatran, while highlighting the importance of information and education about the availability and appropriate use of this recently approved specific reversal agent.
Czech name
—
Czech description
—
Classification
Type
J<sub>imp</sub> - Article in a specialist periodical, which is included in the Web of Science database
CEP classification
—
OECD FORD branch
30205 - Hematology
Result continuities
Project
—
Continuities
I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace
Others
Publication year
2017
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Data specific for result type
Name of the periodical
Journal of Thrombosis and Thrombolysis
ISSN
0929-5305
e-ISSN
—
Volume of the periodical
43
Issue of the periodical within the volume
3
Country of publishing house
US - UNITED STATES
Number of pages
12
Pages from-to
306-317
UT code for WoS article
000395829100004
EID of the result in the Scopus database
2-s2.0-85013103925